Female Pattern Hair Loss (Androgenetic Alopecia): Diagnosis, Treatments & Outlook

Female pattern hair loss (FPHL), or androgenetic alopecia, affects ~40% of women by age 50. Unlike male pattern baldness, it presents as diffuse central thinning with preserved frontal hairline.

Clinical Presentation

  • Ludwig Classification: Type I (mild, central thinning), Type II (moderate, widened part), Type III (severe, near-total vertex loss).
  • Sinclair Scale: 5-stage photographic guide for clinical tracking.
  • Frontal hairline usually maintained; no vertex balding like men.

Pathophysiology

  • Genetic: Polygenic; androgen receptor (AR), aromatase (CYP19A1), Wnt/β-catenin pathway genes.
  • Hormonal: DHT (from testosterone via 5α-reductase) miniaturizes follicles in genetically susceptible women. Androgens may be normal; follicular sensitivity is key.
  • Contributing factors: PCOS, menopause (estrogen decline unmasks androgens), thyroid dysfunction, iron deficiency, medications (androgenic progestins, valproate).

Diagnostic Workup

  • History: onset, pattern, family history, menstrual cycle, medications.
  • Scalp exam: trichoscopy (diversity of hair diameters, peripilar signs, yellow dots).
  • Labs if indicated: CBC, ferritin, TSH, free/total testosterone, DHEAS, prolactin (rule out hyperandrogenism).

Evidence-Based Treatments

FDA-Approved / First-Line

  • Topical minoxidil 2% (women) / 5% (off-label): Prolongs anagen, increases follicular size. 40–60% show stabilization/regrowth at 12 months. Shedding at 2–8 weeks = good sign.
  • Oral minoxidil 0.25–1.25 mg/day: Emerging off-label use; superior adherence, efficacy; monitor for hypertrichosis, edema, tachycardia.

Anti-Androgens (Off-Label, Require Contraception)

  • Spironolactone 50–200 mg/day: Aldosterone antagonist + androgen receptor blockade. First-line for hyperandrogenism/PCOS.
  • Finasteride 1–2.5 mg/day (postmenopausal): 5α-reductase type II inhibitor. Teratogenic (Category X).
  • Dutasteride 0.5 mg/day: Dual 5α-reductase inhibitor; more potent.
  • Cyproterone acetate (combined OCP): Androgen receptor antagonist + gonadotropin suppression.

Adjunctive / Emerging

  • Low-level laser therapy (LLLT): FDA-cleared devices (combs, helmets); modest evidence for density increase.
  • Platelet-rich plasma (PRP): Growth factors; multiple sessions; variable protocols.
  • Microneedling + minoxidil: Enhanced delivery.
  • Hair transplantation: FUE/FUT for stable donor area; artistic design critical for diffuse pattern.

Prognosis & Monitoring

  • Chronic, progressive without treatment.
  • Response assessed at 6–12 months (global photography, trichoscopy, hair mass index).
  • Maintenance therapy lifelong; discontinuation → reversal in 3–6 months.
  • Psychosocial support: significant QoL impact; refer to support groups (NAAF, Alopecia UK).

Women's Health - Related Articles